|
|
Volumn 103, Issue 6, 2005, Pages 1314-1315
|
|
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma [1] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
TRASTUZUMAB;
BREAST CARCINOMA;
CANCER GROWTH;
CANCER INCIDENCE;
CANCER RECURRENCE;
CANCER RISK;
CANCER SURVIVAL;
CENTRAL NERVOUS SYSTEM;
CENTRAL NERVOUS SYSTEM METASTASIS;
FOLLOW UP;
HUMAN;
LETTER;
LONG TERM CARE;
PRIORITY JOURNAL;
PROGNOSIS;
RISK ASSESSMENT;
ADULT;
AGE DISTRIBUTION;
AGED;
ANTIBODIES, MONOCLONAL;
BREAST NEOPLASMS;
CASE-CONTROL STUDIES;
CENTRAL NERVOUS SYSTEM NEOPLASMS;
COHORT STUDIES;
FEMALE;
HUMANS;
INCIDENCE;
MIDDLE AGED;
NEOPLASM STAGING;
PROGNOSIS;
RECEPTOR, ERBB-2;
RISK ASSESSMENT;
SURVIVAL ANALYSIS;
|
|
EID: 14744281021
PISSN: 0008543X
EISSN: None
Source Type: Journal
DOI: 10.1002/cncr.20889 Document Type: Letter |
|
Times cited : (3)
|
|
References (0)
|
